P-SCN-BN-OXO-DO3A试剂 | 1370442-99-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: P-SCN-BN-OXO-DO3A试剂
• 英文名称: 5-((4-Isothiocyanatophenyl)methyl)-1-oxa-4,7,10-triazacyclododecane-4,7,10-triacetic acid, (5S)-
• 英文别名: 2-[(9S)-7,10-bis(carboxymethyl)-9-[(4-isothiocyanatophenyl)methyl]-1-oxa-4,7,10-triazacyclododec-4-yl]acetic acid
• CAS: 1370442-99-1
• 化学式: C₂₂H₃₀N₄O₇S
• 分子量: 494.569
• InChiKey: VRELIIISCCUCHF-IBGZPJMESA-N

物化性质

• 沸点：
  744.3±60.0 °C(Predicted)
• 密度：
  1.35±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -4.7
• 重原子数：
  34
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  175
• 氢给体数：
  3
• 氢受体数：
  12

反应信息

• 作为反应物：
  描述：

  P-SCN-BN-OXO-DO3A试剂 、 (3S,7S,22S)-26-amino-5,13,20-trioxo-4,6,12,21-tetraazahexacosane-1,3,7,22-tetracarboxylic acid 在 N,N-二异丙基乙胺 作用下， 以 二甲基亚砜 为溶剂， 反应 4.0h， 以23%的产率得到9,16,24-trioxo-1-thioxo-1-((4-((4,7,10-tris(carboxymethyl)-1-oxa-4,7,10-triazacyclododecan-2-yl)methyl)phenyl)amino)-2,8,17,23,25-pentaazaoctacosane-7,22,26,28-tetracarboxylic acid
  参考文献：
  名称：

  ⁶⁴Cu-Labeled Inhibitors of Prostate-Specific Membrane Antigen for PET Imaging of Prostate Cancer

  摘要：

  Prostate-specific membrane antigen (PSMA) is a well-recognized target for identification and therapy of a variety of cancers. Here we report five (64)Cu-labeled inhibitors of PSMA, [(64)Cu]3-7, which are based on the lysine-glutamate urea scaffold and utilize a variety of macrocyclic chelators, namely NOTA(3), PCTA(4), Oxo-DO3A(5), CB-TE2A(6), and DOTA(7), in an effort to determine which provides the most suitable pharmacokinetics for in vivo PET imaging. [(64)Cu]3-7 were prepared in high radiochemical yield (60-90%) and purity (>95%). Positron emission tomography (PET) imaging studies of [(64)Cu]3-7 revealed specific accumulation in PSMA-expressing xenografts (PSMA+ PC3 PIP) relative to isogenic control tumor (PSMA- PC3 flu) and background tissue. The favorable kinetics and high image contrast provided by CB-TE2A chelated [(64)Cu]6 suggest it as the most promising among the candidates tested. That could be due to the higher stability of [(64)Cu]CB-TE2A as compared with [(64)Cu]NOTA, [(64)Cu]PCTA, [(64)Cu]Oxo-DO3A, and [(64)Cu]DOTA chelates in vivo.

  DOI：

  10.1021/jm401921j

文献信息

• [EN] CHELATED PSMA INHIBITORS<br/>[FR] INHIBITEURS CHÉLATÉS DU PSMA
  申请人：CANCER TARGETED TECHNOLOGY LLC

  公开号：WO2012174136A1

  公开（公告）日：2012-12-20

  Compounds as defined herein are provided which are useful in (1) diagnostic methods for detecting and/or identifying cells presenting PSMA; (2) compositions comprising a compound of the invention together with a pharmaceutically acceptable diluent; and (3) methods for imaging prostate cancer cells.

  本文定义的化合物可用于：（1）用于检测和/或鉴定表达PSMA的细胞的诊断方法；（2）包含本发明化合物的与药用稀释剂一起的组合物；以及（3）用于成像前列腺癌细胞的方法。
• Chelated PSMA Inhibitors
  申请人：Berkman Clifford

  公开号：US20140241985A1

  公开（公告）日：2014-08-28

  Compounds as defined herein are provided which are useful in (1) diagnostic methods for detecting and/or identifying cells presenting PSMA; (2) compositions comprising a compound of the invention together with a pharmaceutically acceptable diluent; and (3) methods for imaging prostate cancer cells.

  本文提供了化合物，其用于：(1)检测和/或鉴定呈现PSMA的细胞的诊断方法；(2)包含本发明化合物和药学可接受稀释剂的组合物；以及(3)成像前列腺癌细胞的方法。
• Chelated PSMA inhibitors
  申请人：Cancer Targeted Technology

  公开号：US10166301B2

  公开（公告）日：2019-01-01

  Compounds as defined herein are provided which are useful in (1) diagnostic methods for detecting and/or identifying cells presenting PSMA; (2) compositions comprising a compound of the invention together with a pharmaceutically acceptable diluent; and (3) methods for imaging prostate cancer cells.

  本文所定义的化合物可用于：(1) 检测和/或识别呈现 PSMA 的细胞的诊断方法；(2) 由本发明化合物和药学上可接受的稀释剂组成的组合物；(3) 前列腺癌细胞成像方法。
• Albumin-binding PSMA inhibitors
  申请人：Cancer Targeted Technology LLC

  公开号：US11147889B2

  公开（公告）日：2021-10-19

  Provided herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L1 and L2 are each independently a covalent bond or a divalent linking group, R is a detectable label or therapeutic drug and B is an albumin binding moiety. Also provided are compositions including a compound of Formula (I) together with a pharmaceutically acceptable carrier, and methods for imaging prostate cancer cells using a compound of Formula (I).

  本文提供了式 (I) 化合物或其药学上可接受的盐，其中 L1 和 L2 各自独立地为共价键或二价连接基团，R 为可检测标签或治疗药物，B 为白蛋白结合分子。还提供了包括式（I）化合物和药学上可接受的载体的组合物，以及使用式（I）化合物对前列腺癌细胞成像的方法。
• Albumin-Binding PSMA Inhibitors
  申请人：Cancer Targeted Technology LLC

  公开号：US20200061218A1

  公开（公告）日：2020-02-27

  Provided herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L 1 and L 2 are each independently a covalent bond or a divalent linking group, R is a detectable label or therapeutic drug and B is an albumin binding moiety. Also provided are compositions including a compound of Formula (I) together with a pharmaceutically acceptable carrier, and methods for imaging prostate cancer cells using a compound of Formula (I).